CJC-1295 (without DAC) and HGH Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and HGH have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Both compounds affect the gi tract and pituitary, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

HGH

Human Growth Hormone | Somatropin

Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation.

Half-life: 3-4 hours (SC), 20-30 minutes (IV) Typical dose: 1-4 IU daily (0.33-1.33mg); start low and titrate up growth hormone, weight loss, healing
gh directigf1 carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Blood Vessels
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), HGH). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 (without DAC), HGH). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds affect insulin sensitivity (CJC-1295 (without DAC), HGH). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), HGH). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with HGH?

Yes, but with caution. Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and HGH safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and HGH?

Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and HGH?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and HGH has a half-life of 3-4 hours (SC), 20-30 minutes (IV). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs HGH

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.